Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-06-28 00:00:00 ET · period of report 2022-06-24 · accession 0000899243-22-024385 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-28 | 2022-06-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $291.30 | -11.7K | 111.2K | -10% | -$3.41M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-24 | S | D | 11,689 | $291.30 | 111,153 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $291.30 (range $291.00 to $291.49). (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |